Exact Sciences (EXAS) Proxy Filing summary

Executive summary

• Announced a merger agreement where the company will become a wholly owned subsidiary of Abbott, with a per share merger consideration of $105.00 in cash for common stockholders.

• Supplemental proxy disclosures were made in response to shareholder litigation alleging insufficient or misleading information in the original proxy statement.

• Forward-looking statements highlight risks including regulatory approvals, potential competing offers, transaction costs, and impacts on business relationships and personnel.

Voting matters and shareholder proposals

• Shareholders are asked to vote on the adoption of the merger agreement with Abbott.

• Litigation from shareholders seeks to enjoin the merger or obtain damages, alleging disclosure deficiencies.

Executive compensation and say-on-pay

• Financial projections include adjustments for stock-based compensation and a $75 million licensing agreement expense, impacting adjusted EBITDA for 2025 and 2026.